LEO Pharma

LEO Pharma appoints Paul Navarre new member of its Board of Directors


Ballerup, Denmark, August 31, 2022 – LEO Pharma today announced the appointment of Paul Navarre as new member of its Board of Directors.

Paul Navarre currently serves as chairman of the Board of Directors at HTL (dermatology) and Arkopharma (Dietary Supplements), as Vice Chairman of Hallura (dermatology) and as Strategic Advisor to other companies. From 2017-2020 he held the position as CEO of Ferring US Holding subsequent to ten years at Allergan, among other as President of International Operations (global except US) and President of EAME (Europe, Middle East and Africa). Prior to that, he spent 15 years at Procter & Gamble managing multiple countries and global brands in pharmaceuticals and Health and beauty care.

Paul Navarre has a solid track record of delivering sustainable top line growth and building high performance organizations in the specialty pharmaceutical business through scientific innovation and customer centric approaches.

“With his impressive career, Paul brings extensive strategic and commercial experience from the global biotech and dermatology market, that will be of great value to LEO Pharma in its ambitions to create future growth and become a top five company within medical dermatology. I am excited to be working together with Paul going forward”, said Jesper Brandgaard, chairman of the Board of Directors at LEO Pharma.

“It’s a privilege to join the Board of Directors at LEO Pharma at this time in the company’s history. With its ongoing transformation, many steps have already been taken to position the company for future growth and I look much forward to being part of continuing this development”, said Paul Navarre.

Paul Navarre was elected one of the Top 100 Most Inspiring People by PharmaVoice in 2019. In 2021 he completed the Insead Corporate Governance Course.


Henrik Heskjær
+45 3140 6180

About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO Pharma  

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

LEO Pharma presents new Adtralza® safety data in moderate-to-severe atopic dermatitis at the 31st EADV Congress8.9.2022 14:15:00 CEST | Press release

• An interim safety analysis from ECZTEND, an open-label, 5-year extension trial, demonstrated consistent safety from the parent trials for up to 3.5 years of Adtralza® (tralokinumab) treatment in adult patients with moderate-to-severe atopic dermatitis.1 • Exposure-adjusted incidence rates of adverse events of special interest, including conjunctivitis, eczema herpeticum, and skin infections requiring systemic treatment, were generally lower than rates reported during the placebo-controlled period up to Week 16 and declined over time.1

LEO Pharma appoints new Executive Vice President of Global Product Supply3.8.2022 14:29:55 CEST | Press release

Ballerup, Denmark, August 03, 2022 – LEO Pharma A/S announced today the appointment of Sven Hauptmann as its new Executive Vice President of Global Product Supply, effective August 1, 2022. Sven joins LEO Pharma with more than 25 years of international experience from Roche where he has held numerous leadership positions within supply chain and manufacturing. He comes with a strong track record delivering world-class results e.g., as Site Lead for Roche’s production site in Ireland, Vice President for Small Molecules Manufacturing and most recently as Senior Vice President for Global Drug Product Manufacturing. Sven holds a Ph.D. in Chemistry from the Technical University in Darmstadt, Germany and an Executive MBA from Northwestern University – Kellogg School of Management. “I am delighted and proud to welcome Sven to LEO Pharma. I strongly believe he will bring significant value to our business and drive the transformation agenda in our global product supply as we progress on our ambi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom